Cross-talk among novel programmed cell death pathways: a decisive network in renal ischemia-reperfusion injury Authors: Yalin Lou, Jueheng Wu, Shilei Cheng, Guanghan Wu, Liang Guo, Fan Yang, Jianbo Wu Published: 2026 ABSTRACT Renal ischemia-reperfusion injury (IRI) is a major pathological driver of acute kidney injury (AKI), for which effective therapeutic strategies remain lacking. Recently, novel forms of programmed cell death (PCD), including pyroptosis, ferroptosis, cuproptosis and necroptosis, have been identified as key mediators of tubular damage and inflammation in renal IRI. This review delineates a hierarchically organized and spatiotemporally regulated PCD network, positioning it as a central determinant of cellular fate following renal IRI. We systematically characterize the distinct molecular signatures of each death modality and critically examine their extensive crosstalk within the pathological renal microenvironment. Synthesizing current evidence, we demonstrate that this network operates in a cell type- and phase-specific manner, driving a vicious cycle of inflammation and oxidative stress. Targeting this interconnected network rather than isolated pathways represents a paradigm shift. We critically assess current therapeutic strategies and their limitations in the context of this network. Finally, we propose a forward-looking roadmap that emphasizes combination therapies guided by spatial transcriptomics, patient stratification using PCD-specific biomarkers and the development of smart nanosystems capable of dynamically modulating key network nodes. Deciphering and therapeutically intervening in this PCD network is pivotal for developing effective treatments for renal IRI. Introduction Renal ischemia-reperfusion injury (IRI) is a pathological phenomenon in which tissue damage is exacerbated upon restoration of blood flow following an ischemic event. In severe cases, it may lead to irreversible renal injury (1, 2). Clinically, renal IRI is primarily manifested by elevated serum creatinine (Scr) and blood urea nitrogen (BUN), oliguria or anuria, and may be accompanied by complications such as edema, hypertension, hyperkalemia, metabolic acidosis and infections. In severe instances, it can progress to acute renal failure (3). The kidney receives an exceptionally rich blood supply, accounting for approximately 20-25% of cardiac output. This high-perfusion characteristic renders it particularly vulnerable to ischemia. In recent years, with the widespread application of technologies such as cardiopulmonary bypass, arterial bypass grafting and organ transplantation, the incidence and mortality of acute kidney injury (AKI) induced by renal IRI have been rising annually (4). Renal IRI poses a significant clinical challenge and underlies the development of AKI in various contexts ranging from cardiac surgery to renal transplantation (5). Paradoxically, the restoration of blood flow triggers oxidative stress and inflammatory cascades. These events ultimately lead to the death of renal tubular epithelial cells and consequent organ dysfunction. Owing to the complexity and redundancy of the injury pathways, therapeutic translation has remained unsatisfactory despite decades of research efforts. Previous studies have predominantly focused on apoptosis and autophagy. Although these processes are crucial, clinical translation based on their regulation has been limited. This suggests the involvement of other key cell death mechanisms in the complex pathology of renal IRI. Based on their regulatory mechanisms, cell death can be classified into two major categories, namely accidental cell death and regulated cell death (6). Accidental cell death, also known as cell necrosis, is a non-programmed, unregulated form of death directly caused by intense physical, chemical or biological damage. This process leads to cellular rupture and the release of intracellular contents, typically accompanied by a significant inflammatory response. In contrast, regulated cell death is precisely controlled by specific intracellular signaling pathways and can be modulated through genetic or pharmacological interventions. The past decade has witnessed the discovery and characterization of several novel, genetically regulated forms of programmed cell death (PCD), including pyroptosis, ferroptosis, cuproptosis and necroptosis (7–9). Each is defined by a distinct molecular mechanism. Pyroptosis occurs via Gasdermin pore formation activated by inflammasomes. Ferroptosis proceeds through iron-dependent lipid peroxidation. Cuproptosis is driven by copper-induced mitochondrial proteotoxic stress. And necroptosis is executed by the RIPK1/RIPK3/MLKL axis. Here, RIPK1 stands for receptor-interacting serine/threonine-protein kinase 1, RIPK3 for receptor-interacting serine/threonine-protein kinase 3 and MLKL for mixed lineage kinase domain-like protein. Compelling evidence now places these pathways at the center of the pathogenesis of renal IRI (10). However, viewing these death programs as isolated, parallel pathways is an oversimplification that may constrain therapeutic efficacy. Within the intricate microenvironment of the post-ischemic kidney, these pathways engage in intensive molecular crosstalk. They thereby form an integrated cell death network (11). This network exhibits properties of redundancy, priming and switch-like behavior. Inhibiting one pathway may divert cellular fate to another, while activating one can explosively ignite others. Therefore, comprehending the network’s architecture and logic is paramount. This includes understanding its key hubs, positive feedback loops and cell-type-specific connections. A comprehensive literature search was performed in the PubMed and Google Scholar databases for articles published up to the present. The search terms included combinations of several keywords. These included “renal ischemia-reperfusion injury”, “acute kidney injury”, “programmed cell death”, “pyroptosis”, “ferroptosis”, “cuproptosis”, “necroptosis”, “autophagy”, “apoptotic”, “PCD network”, “therapeutic targeting”, “combination therapy”, among others. Only peer-reviewed original research articles and reviews written in English were considered. The reference lists of retrieved articles were also manually screened to identify additional relevant studies. Given the narrative nature of this review, studies were selected based on their relevance to the conceptual framework of a spatiotemporally regulated PCD network in renal IRI. Emphasis was placed on emerging mechanisms and therapeutic strategies. This review aims to synthesize existing knowledge by constructing a dynamic network model of the interactions among these novel PCD pathways in renal IRI, rather than merely cataloging them. We will first outline the core mechanisms and evidence for each death modality. We will then focus on their crosstalk and argue that the emergent properties of this network, rather than the sum of its parts, determine the magnitude of renal injury. Finally, we will critically evaluate therapeutic strategies targeting network nodes and propose a future research agenda. This agenda will focus on system-level approaches to modulate this decisive network for renal protection. Novel PCD pathways in renal IRI: core mechanisms Pyroptosis: the inflammatory executor Pyroptosis is a lytic and pro-inflammatory form of PCD mediated by Gasdermin family proteins, primarily Gasdermin D (GSDMD) (12). In renal IRI, its activation involves the coordinated action of both canonical and non-canonical inflammasome signaling pathways (Figure 1a). During renal IRI, the NLR family pyrin domain containing 3 (NLRP3) inflammasome is significantly activated in renal tissue. Activated caspase-1 cleaves GSDMD, releasing its N-terminal fragment. This fragment oligomerizes to form plasma membrane pores, leading to the release of potent pro-inflammatory cytokines, such as IL-1β and IL-18. These events are closely associated with renal tubular epithelial cell damage and the elevation of renal function markers, including Scr and BUN (13, 14). In addition to the canonical NLRP3/caspase-1 pathway, renal IRI also upregulates the expression of caspase-11, a component of the non-canonical pathway. Activated caspase-11 cleaves GSDMD, thereby triggering pyroptosis in renal tubular epithelial cells (15). Notably, Gasdermin E (GSDME) is highly expressed in renal tubules and can be cleaved by caspase-3. This process converts an apoptotic signal into a pyroptotic outcome, rendering GSDME a critical hub for the convergence of different cell death pathways (16). Mechanisms of pyroptosis, ferroptosis and cuproptosis. (a) Pyroptosis. Renal IRI triggers the assembly and activation of the NLRP3 inflammasome. Activated caspase-1 processes pro-IL-1β and pro-IL-18 into mature IL-1β and IL-18. It also cleaves GSDMD, releasing GSDMD-NT. GSDMD-NT oligomerizes and forms pores in the plasma membrane. Concurrently, renal IRI upregulates caspase-11 expression. Activated caspase-11 directly cleaves GSDMD, executing pyroptosis independently of the NLRP3 inflammasome. (b) Ferroptosis. Its core mechanism is driven by iron-dependent lipid peroxidation. Pathological stimuli, such as ischemia-reperfusion, lead to intracellular ROS accumulation and iron overload. These two factors act synergistically via the Fenton reaction. This reaction catalyzes the catastrophic accumulation of phospholipid hydroperoxides. The result is oxidative damage and functional loss of cellular membranes, especially mitochondrial membranes. The GSH-GPX4 antioxidant system serves as the core cellular defense against this process. Loss of its function, including GPX4 inactivation or GSH depletion, serves as the key switch that triggers ferroptosis. (c) Cuproptosis. The highly active Cu+ enters mitochondria. It directly attacks and disrupts the structure of Fe-S cluster proteins, leading to their disassembly. The loss of Fe-S clusters causes lipoylated enzymes, such as DLAT, to misfold, aggregate and lose function. This triggers severe mitochondrial proteotoxic stress, ultimately resulting in cell death. Ferroptosis: a metabolic catastrophe Ferroptosis is an iron-dependent form of cell death driven by the catastrophic accumulation of phospholipid hydroperoxides (17). Its core defense system is the glutathione (GSH)-glutathione peroxidase 4 (GPX4) axis. Depletion of GSH or inactivation of GPX4 abolishes the reduction of lipid hydroperoxides, leading to membrane damage (18–20). In the pathological progression of renal IRI, the activation of ferroptosis exhibits distinct spatiotemporal characteristics. During the ischemic phase, hypoxia leads to the accumulation of reactive oxygen species (ROS) and the release of iron ions, laying the metabolic groundwork for ferroptosis. The reperfusion phase, however, paradoxically triggers even more intense oxidative stress upon the restoration of oxygen supply. This, combined with iron overload, creates a synergistic effect. It initiates explosive lipid peroxidation through the Fenton reaction, a scenario aptly described as a “perfect storm” (21, 22) (Figure 1b). Renal tubular epithelial cells are highly sensitive to oxidative damage and consequently undergo widespread death. Their characteristic pathological hallmarks include mitochondrial shrinkage and loss of cristae, which serve as morphological evidence of ferroptosis. Ferroptosis is not a “silent” death. Dying cells release damage-associated molecular patterns (DAMPs). These DAMPs activate the innate immune system, recruit inflammatory cell infiltration and promote the activation of myofibroblasts as well as extracellular matrix deposition. This process further exacerbates renal interstitial inflammation and fibrosis following acute injury (23, 24). Importantly, ferroptosis can occur synchronously across multiple tubules, suggesting a coordinated and propagative mechanism of injury. Cuproptosis: metal-induced proteotoxicity Cuproptosis is a newly defined cell death pathway. It is triggered by excessive copper binding to lipoylated enzymes in the tricarboxylic acid (TCA) cycle. This binding leads to enzyme aggregation, functional loss and proteotoxic stress, ultimately culminating in cell death (25) (Figure 1c). Copper homeostasis is tightly regulated and its disruption is implicated in disease. Although recent studies have begun to elucidate the role of cuproptosis in renal IRI, the evidence remains preliminary and requires further validation. At this stage, cuproptosis should be regarded as a highly promising emerging hypothesis, avoiding equating its research maturity entirely with that of ferroptosis or pyroptosis. Emerging evidence suggests that cuproptosis may occur in renal tubular epithelial cells following renal IRI (26). Preliminary observations indicate that it may manifest as cellular edema, nuclear pyknosis and functional impairment. Prolonged or severe cuproptosis could further lead to tubular atrophy and interstitial fibrosis, thereby exacerbating structural damage to kidney tissue (26). Iron overload may increase cellular susceptibility to cuproptosis, possibly by disrupting iron-sulfur cluster biogenesis (27). This finding suggests a potential mechanism that dysregulation of iron homeostasis might serve as a critical bridge linking ferroptosis and cuproptosis. These are two distinct metal-associated cell death modalities. The morphological characteristics and functional consequences of cuproptosis position it as a relevant yet currently underexplored contributor to renal IRI. Other key players: the contextual dual roles of necroptosis and autophagy Necroptosis is a programmed form of necrosis activated upon inhibition of apoptosis, for instance when caspase activity is blocked. It is initiated by death receptors or pattern recognition receptors (28). The activation of this pathway is caspase-independent and is instead driven by a signaling cascade that involves RIPK1, RIPK3 and their common substrate MLKL (29). In renal IRI, signals such as hypoxia and oxidative stress can significantly upregulate the activity of key molecules in the necroptotic pathway, including RIPK1, RIPK3 and MLKL. This cascade mediates the programmed rupture of renal epithelial cells. This rupture amplifies local inflammation through the release of DAMPs, thereby exacerbating renal function impairment (30, 31). Autophagy, as one of the most extensively studied traditional cell death modalities, exhibits a context-dependent role in renal IRI. The protective or detrimental function of autophagy depends primarily on the timing and intensity of its activation. During the ischemic phase, moderate autophagy can clear damaged mitochondria and oxidized proteins. This provides energy and substrates for cell survival, thus exerting a protective effect. However, during the reperfusion phase, excessive or dysregulated autophagy may non-selectively degrade essential cellular components or engage in crosstalk with apoptotic signals. It can then transform into a factor that promotes cell death and aggravates tissue damage (32). Key determinants of this shift include the duration of ischemia, the phase of the IRI process and the extent of autophagic flux (33). The integrated PCD network: crosstalk as a core driver of injury Cell death pathways do not operate in isolation. Instead, they are interconnected through a complex molecular network that forms a sophisticated system of cross-regulation. This interaction manifests mainly at three levels. Different death pathways share key regulatory molecules. One example is the dual role of the caspase family in both apoptosis and pyroptosis. There is also a typical sequential relay pattern. In this pattern, the inhibition of apoptosis can shift cellular fate towards necroptosis. Moreover, different death modalities can transform into one another. For instance, the ferroptosis inducer Erastin can simultaneously suppress apoptotic pathways. This intricate network of interactions is of significant importance in the pathogenesis, progression and treatment of diseases. It provides a new theoretical foundation for developing combination therapies for complex diseases. The inflammatory axis: pyroptosis and other death modalities fuel a vicious cycle Pyroptosis and necroptosis are co-activated and engage in bidirectional amplification. This creates a potent inflammatory microenvironment. They share common triggers and molecular bridges. DAMPs released from damaged cells simultaneously activate the RIPK1/RIPK3 cascade and the toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-κB) pathway, which primes NLRP3 inflammasome assembly. Crucially, the necroptosis executioner protein MLKL can promote NLRP3 inflammasome activation and IL-1β maturation independently of GSDMD (34, 35). Under physiological conditions, GSDMD-mediated pyroptosis leads to rapid cell lysis. This effectively preempts the slower activation of the necroptosis and thereby exerts a natural inhibitory effect. However, in renal IRI, this inhibition is abolished when GSDMD function is impaired or its expression is insufficient. Consequently, renal tubular epithelial cells and macrophages become significantly more susceptible to necroptosis (36). This establishes a positive feedback loop. Cell lysis caused by necroptosis releases DAMPs, which activate inflammasomes in neighboring cells. This leads to pyroptosis and cytokine release. These cytokines create a pro-inflammatory microenvironment that further sensitize cells to TNFα-mediated necroptosis, driving uncontrolled inflammation and exacerbated tissue damage. These findings reveal experimentally validated functional interactions between pyroptosis and necroptosis, as documented by MLKL-dependent NLRP3 activation and GSDMD-mediated preemption of necroptosis. ROS serve as the core initiating signal for both pyroptosis and apoptosis. In renal IRI, ROS activate the NLRP3 inflammasome, directly inducing pyroptosis. Subsequently, IL-1β and IL-18 exacerbates inflammation and oxidative stress. This creats a positive feedback loop that amplifies tissue damage and promotes further cell death (Figure 2a). Concurrently, ROS induce mitochondrial membrane potential collapse and cytochrome C release. This activates the caspase-9/caspase-3 cascade to execute apoptosis (37). Furthermore, in hypoxia- and ischemia-induced neuronal injury, pyroptosis can activate apoptosis-related proteins (38). The canonical pyroptosis pathway may shift towards apoptosis (39). The non-canonical pathway can also indirectly induce apoptosis (40). Conversely, apoptosis effectors can promote NLRP3 inflammasome activation via the cellular FLICE-like inhibitory protein (c-FLIP) complex or the NF-κB pathway (41, 42). FAS-associated death domain protein (FADD) also promotes the activation of the NLRP3 inflammasome and caspase-1, thereby regulatig pyroptosis (43). Notably, GSDME is highly expressed in renal tubular epithelial cells. In these cells, caspase-3 cleaves GSDME, thereby converting apoptosis into pyroptosis (44). Conversely, caspase-3 may also inhibit pyroptosis by cleaving activated GSDMD-NT (45), indicating bidirectional regulation. This body of evidence confirms functional crosstalk between pyroptosis and apoptosis, as shown by FADD-dependent NLRP3 activation and caspase-3-mediated GSDME cleavage. This dynamic network enables signal conversion and amplification, significantly expanding the scope and intensity of injury. Interactions between different cell death modalities. (a) Inflammatory factors released from pyroptotic cell lysis exacerbate local inflammation and oxidative stress. This microenvironment in turn promotes apoptosis in more cells. Simultaneously, under specific conditions, apoptotic signals can be converted into pyroptosis. Damage-associated molecules released by both modalities further activate immune responses. This forms a self-reinforcing positive feedback loop that continuously amplifies tissue damage and cell death. (b) The regulation of pyroptosis by autophagy exhibits a complex “double-edged sword” characteristic. Autophagy suppresses the initiation and execution of pyroptosis by clearing damaged mitochondria and selectively degrading key activated pyroptosis-related proteins. However, under severe stress, excessive or dysregulated autophagy fails to effectively clear damage signals. Instead, it switches to promoting pyroptosis. (c) The death of renal tubular epithelial cells exhibits a marked spatially synchronized pattern. Ferroptosis is a key mechanism underlying this pathological phenomenon. When the local tissue’s redox defense system collapses, signals such as peroxidized lipids released from damaged cells can diffuse among neighboring cells. This creates a self-amplifying wave of damage, driving clusters of cells to synchronously enter an irreversible death program. Consequently, this causes continuous destruction of the tubular structure. (d) Cell death displays a temporally biphasic pattern. The first wave is directly triggered by the initial insult, primarily manifesting as apoptosis or acute necrosis. Subsequently, factors persistently present in the microenvironment activate death receptor pathways. This initiates a delayed but more extensive second wave of death. This phase is dominated by necroptosis. Its executioner protein MLKL mediates membrane damage and releases pro-inflammatory substances. This exacerbates oxidative stress and local inflammation. The fate decision between apoptosis and necroptosis is primarily determined by the activity status of caspase-8. Pyroptosis and autophagy form a complex “double-edged sword” network, collectively determining cell fate. Typically, autophagy is cytoprotective by clearing damaged mitochondria and abnormal protein aggregates. In contrast, pyroptosis causes plasma membrane rupture and amplifies inflammation via IL-1β (46). In various kidney injury diseases, autophagy inhibits pyroptosis at multiple levels (47–49). Autophagy clears damaged mitochondria. This reduces the production of mitochondrial ROS (mtROS), which is a key trigger for NLRP3 inflammasome activation (50). Furthermore, autophagy degrades components of the activated NLRP3 inflammasome. For instance, sequestosome 1 (P62) mediates the degradation of apoptosis-associated speck-like protein containing a CARD (ASC) specks (51). Tripartite motif containing 20 (TRIM20) targets both NLRP3 and pro-caspase-1 (52). Ubiquitin specific peptidase 18 (USP18) mediates ubiquitination of GSDMD, subsequently mediating its degradation (53). Additional, immunity-related GTPase family M protein (IRGM), ubiquitin specific peptidase 5 (USP5) and galectin-9 (LGALS9) similarly regulate pyroptosis through analogous mechanisms (54–56). However, under IRI stress, excessive autophagy fails to provide protection and instead depletes cellular components. It paradoxically amplifies pyroptotic signaling. Conversely, pyroptosis driven inflammation further disrupts autophagic homeostasis, creating a positive feedback loop (57–59) (Figure 2b). Moreover, in AKI, autophagy activates caspase-3 and caspase-8, which then drive GSDME-mediated pyroptosis (60, 61). These findings establish experimentally supported crosstalk between pyroptosis and autophagy, as reflected by autophagy-mediated degradation of NLRP3 inflammasome components, as well as by autophagy-dependent activation of the caspase-3/caspase-8 axis that drives GSDME-mediated pyroptosis. In renal IRI, pyroptosis and ferroptosis constitute a mutually reinforcing positive feedback loop. This loop collectively exacerbates the loss of renal tubular epithelial cells and the deterioration of renal function (62–64). In neonicotinoid-induced kidney injury, ferroptosis releases high mobility group protein B1 (HMGB1). HMGB1 then activates the HMGB1-receptor for advanced glycosylation end products (RAGE)/TLR4/NF-κB signaling pathway to trigger pyroptosis (65). Furthermore, free iron accumulated during ferroptosis catalyzes the production of ROS via the Fenton reaction. In diquat-induced kidney injury, these ROS further activate caspase-3, which then cleaves GSDME to promote pyroptosis (66). On the other hand, pyroptosis releases inflammatory cytokines. These cytokines weaken antioxidant defense system and amplify oxidative stress, further promoting ferroptosis. Within this regulatory network, GPX4 acts as a key regulatory factor. In cadmium-induced nephrotoxicity, GPX4 directly inhibits ferroptosis by reducing phospholipid hydroperoxides. Simultaneously, by maintaining mitochondrial function and reducing mtROS generation, GPX4 indirectly inhibits NLRP3 inflammasome activation (67). The nuclear factor erythroid 2-related factor 2 (Nrf2)/kelch-like ECH-associated protein 1 (KEAP1) axis upregulates heme oxygenase-1 (HO-1) and GPX4, promoting GSH synthesis and inhibiting ferroptosis (68, 69). In osteoarthritis, Nrf2 also exhibits a dual function in pyroptosis. It can promote pyroptosis by activating the NLRP3 and absent in melanoma 2 (AIM2) inflammasomes, yet it can also inhibit pyroptosis by reducing intracellular ROS levels (70). Overall, these findings substantiate experimentally supported crosstalk between pyroptosis and ferroptosis, as illustrated by ferroptosis-derived HMGB1 and ROS that trigger pyroptosis, as well as shared regulatory nodes including Nrf2 that bidirectionally modulate both pathways. The metabolic stress axis: ferroptosis and other cell death modalities induce metabolic imbalance In renal injury, autophagy serves as a crucial upstream regulator of ferroptosis, forming a complex bidirectional regulatory network (71). In AKI, chaperone-mediated autophagy degrades GPX4, ultimately triggering ferroptosis (72, 73). Various forms of selective autophagy also regulate ferroptosis through distinct mechanisms (74). In IRI, ferritinophagy releases iron ions into the cytosol. This in turn catalyzes ROS production via the Fenton reaction, ultimately induces ferroptosis (75). In cisplatin-induced nephrotoxicity, mitophagy reduces ROS levels, leading to a decrease in HO-1. The decline in HO-1 alleviates its inhibitory effect on GPX4, thereby inhibiting ferroptosis (76). Concurrently, lipophagy promotes lipid peroxidation by releasing fatty acids (77, 78). In hepatocellular carcinoma, reticulophagy inhibits ferroptosis by alleviating endoplasmic reticulum (ER) stress (79, 80). In neuronal and intervertebral disc degeneration, lysophagy inhibits ferroptosis by maintaining iron metabolic homeostasis (81, 82), yet it can also promote ferroptosis by degrading GPX4 (83). Acyl-CoA synthetase long-chain-fatty-acid--CoA ligase 4 (ACSL4) is a key promoter of ferroptosis. It drives ferroptotic by mediating the formation of lipid peroxidation substrates (84). In addition, ACSL4 influences autophagy via the protein kinase AMP-activated catalytic subunit alpha 1 (AMPK)/mammalian target of rapamycin (mTOR) signaling pathways and impedes autophagosome formation by inhibiting proton pump function (85, 86). Conversely, in diabetic retinopathy, the degradation of ACSL4 via the chaperone-mediated autophagy pathway can effectively inhibit ferroptosis (87). These findings experimentally validate functional crosstalk between autophagy and ferroptosis, as demonstrated by chaperone-mediated GPX4 degradation, ferritinophagy-driven iron release, mitophagy-mediated ROS reduction, lipophagy-promoted lipid peroxidation, reticulophagy-mediated ER stress alleviation, lysophagy-dependent iron homeostasis and ACSL4-dependent autophagy regulation. In sepsis-induced AKI, ferroptosis and apoptosis form a synergistic amplification network through shared mitochondrial damage and oxidative stress (88). Apoptosis induced mitochondrial outer membrane permeabilization (MOMP) releases cytochrome c and dysregulates iron metabolism. This promotes the Fenton reaction, accelerates lipid peroxidation and facilitates the transition from apoptosis to ferroptosis. More critically, a positive feedback loop exists between the two pathways. ROS generated during the execution phase of apoptosis further inactivates GPX4. Conversely, lipid peroxides accumulated during ferroptosis exacerbates mitochondrial damage, thereby accelerating apoptosis. In cancer, ferroptosis induces ER stress and the unfolded protein response (UPR). This activates the DNA damage inducible transcript 3 (CHOP)/p53-upregulated modulator of apoptosis (PUMA) axis to initiate apoptosis (89). Conversely, cellular tumor antigen p53 (P53) exerts dual regulation on ferroptosis. It promotes ferroptosis by suppressing the function of solute carrier family 7 member 11 (SLC7A11) and GPX4. On the other hand, it inhibits ferroptosis by interacting with dipeptidyl peptidase IV (DPP4) (90, 91). ACSL4 serves as a crucial molecular hub connecting ferroptosis and apoptosis. It promotes fatty acyl-CoA generation, enhancing oxidative stress and activating the intrinsic apoptotic pathway (92, 93). However, in cancer, during ferroptosis, fatty acid oxidation-induced signal transducer and activator of transcription 3 (STAT3) upregulates ACSL4 expression, which paradoxically maintains mitochondrial integrity and suppresses apoptosis (94). Synthesizing these findings, experimental evidence supports functional crosstalk between ferroptosis and apoptosis, as indicated by MOMP-driven iron dysregulation that promotes ferroptosis, CHOP-PUMA axis activation by ferroptosis that initiates apoptosis, p53-dependent bidirectional regulation of ferroptosis and ACSL4 as a molecular hub connecting both pathways. In renal injury, the death of renal tubular epithelial cells exhibits a synchronized pattern, with ferroptosis as a primary driver. Within a localized area, once the antioxidant defense system collapses, adjacent cells enter an irreversible death program almost simultaneously (Figure 2c). Notably, ferroptosis and necroptosis form a complex bidirectional network. Ferroptosis derived lipid peroxides activate the RIPK1/RIPK3/MLKL pathway, thereby amplifying necroptosis. On the other hand, MLKL causes potassium efflux, activating the NLRP3 inflammasome and creating a pro-oxidative stress microenvironment conducive to ferroptosis (95). In addition, ferroptosis can also inhibit necroptosis. Ferroptosis pores trigger calcium influx, activating the endosomal sorting complexes required for transport (ESCRT)-III complex. The ESCRT-III complex repairs membrane pores to slow ferroptosis and inhibit MLKL-mediated necroptosis (96). In acute kidney failure, ACSL4 bridges the two death pathways. Certain lipid products it generates create an environment favorable for MLKL oligomerization and membrane pore formation (97). Furthermore, cysteine metabolism plays a central role in their cross-regulation. On one hand, mtROS drive the autophosphorylation of RIPK1, thereby initiating necroptosis (98). On the other hand, cysteine promotes GSH synthesis, which in turn inhibits ferroptosis (99). In melanoma, blocking this system leads to ROS accumulation, simultaneously inducing both death modalities (100). The molecular chaperone heat shock protein 90 homolog (HSP90) plays a dual role in this network. In neurons, HSP90 promotes the formation of the RIPK1/RIPK3 necrosome complex, thereby facilitating necroptosis (101). It can also mediate the degradation of GPX4, activating ferroptosis (102). More importantly, in cerebral IRI, HSP90 overexpression can simultaneously activate both death pathways via the HSP90–GCN2–ATF4 signaling axis. GCN2 denotes the eIF-2-alpha kinase and ATF4 stands for activating transcription factor 4 (103). Additionally, in osteoblastic cells, iron overload also promotes necroptosis by elevating ROS levels (104). The above findings demonstrate experimentally supported interplay between ferroptosis and necroptosis, as manifested by ferroptosis-derived lipid peroxides that activate RIPK1/RIPK3/MLKL, MLKL-driven potassium efflux that promotes ferroptosis, ESCRT-III-mediated membrane repair that inhibits necroptosis, ACSL4-generated lipid products that facilitate MLKL oligomerization, cysteine metabolism blockade and the HSP90-GCN2-ATF4 axis that simultaneously activates both pathways. In cisplatin-induced AKI, ferroptosis and cuproptosis do not occur in isolation. Instead, they promote each other through shared axes of metabolic imbalance and oxidative stress, forming a synergistically amplified injury network. Ferroptosis exacerbates mitochondrial damage through lipid peroxidation, which in turn promotes cuproptosis. Conversely, mitochondrial collapse induced by cuproptosis further weakens cellular antioxidant capacity, thereby accelerating ferroptosis. Iron overload downregulates proteins involved in iron-sulfur cluster biogenesis, including the iron-sulfur cluster assembly enzyme (ISCU) and the HIRA-interacting protein 5 (NFU1). Iron-sulfur clusters serve as essential cofactors for numerous mitochondrial enzymes, including those involved in copper metabolism. The destabilization of these clusters increases susceptibility to cuproptosis, rendering mitochondria more vulnerable to copper-induced protein aggregation. Mitochondrial dysfunction serves as a common hub for both ferroptosis and cuproptosis. The hallmarks of ferroptosis include mitochondrial cristae reduction and increased membrane density, with GPX4 inactivation leading to oxidative damage of the mitochondrial membrane. Cuproptosis, on the other hand, directly targets mitochondrial TCA cycle enzymes, causing their aggregation and subsequent respiratory chain collapse (105). Collectively, the data support functional crosstalk between ferroptosis and cuproptosis, as revealed by iron overload-induced destabilization of iron-sulfur clusters that sensitizes tubular cells to cuproptosis and mitochondrial dysfunction as a shared hub for both pathways. Interactions between other cell death modalities Autophagy and necroptosis maintain a dynamic, mutually restrictive equilibrium. Moderate autophagy degrades damaged mitochondria and oxidative stress products, indirectly suppressing necroptosis. Furthermore, autophagosomes directly engulf and degrade RIPK1 and RIPK3, negatively regulating this pathway. However, excessive autophagic flux engages in crosstalk with necroptotic signals. It then exhibits a pro-death phenotype that synergistically exacerbates tubular damage. Notably, once necroptosis is activated, MLKL-mediated membrane rupture triggers inflammation and disrupts the integrity of autophagic flux, pushing it toward a destructive state. Necrotic cells also recruit inflammatory cells and release DAMPs, persistently activating death receptor pathways. Ultimately, this forms a vicious cycle of “autophagy-necroptosis-inflammation”, collectively driving renal injury (106–108). RIPK3 mediates the phosphorylation and activation of AMPK. Activated AMPK enhances the activity of unc-51-like kinase 1 (ULK1) and beclin-1, thereby promoting autophagy (109). Furthermore, in cardiac IRI, phosphorylation of RIPK activates calcium/calmodulin-dependent protein kinase (CaMKII), which induces the opening of the mitochondrial permeability transition pore (MPTP) and triggers mitophagy via the RIPK3-PGAM5-Drp1 signaling axis. Here, PGAM5 stands for phosphoglycerate mutase family member 5 and Drp1 stands for density-regulated protein (110, 111). Conversely, in cisplatin-induced nephrotoxicity, ROS positively regulate necroptosis by inducing MPTP opening and activating the RIPK1/RIPK3/MLKL signaling pathway (112). They can also promote the autophosphorylation of RIPK1, enhancing its interaction with RIPK3 and thereby facilitating the assembly of the necrosome complex (113). Taken as a whole, these findings experimentally substantiate functional crosstalk between autophagy and necroptosis, as evidenced by RIPK3-mediated autophagy activation and autophagy-derived ROS that positively regulate necroptosis. In renal IRI, apoptosis and autophagy are tightly coupled through oxidative stress and inflammatory responses. Their interaction exhibits a time- and dose-dependent dynamic evolution (114–116). During the early stage, autophagy exerts a protective, antagonistic effect. It degrades caspase-8, thereby blocking extrinsic apoptotic signaling. In addition, autophagy suppresses cytochrome c release and blocks the intrinsic apoptotic pathway (117). However, as injury progresses, autophagy transforms into a pro-apoptotic synergistic mechanism. P62-mediated degradation of Fas-associated protein-tyrosine phosphatase 1 (Fap-1) enhances Fas phosphorylation, increasing cellular sensitivity to apoptosis (118). Autophagosomes engulf mitochondria to maintain the immunologically silent state of apoptosis (119). Autophagy-related protein 12 (ATG12) inhibits the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia 1 (Mcl-1), thereby activating BCL2 associated X protein (BAX) (120). Additionally, truncated autophagy protein 5 (ATG5) alters MOMP and activates the caspase cascade (121). Concurrently, in ovarian cancer, apoptotic effector caspases, such as caspase-3, -6, -7, -8, and -9, specifically cleave Beclin-1 and autophagy-related protein 3 (ATG3). This disrupts the integrity of autophagic flux (122, 123). Notably, in renal IRI, B-cell lymphoma extra-large (Bcl-xL) interacts with Beclin-1 to constitutively inhibit autophagosome formation. Simultaneously, by stabilizing the mitochondria, it prevents cytochrome c release. Changes in its expression levels influence the balance between autophagy and apoptosis, ultimately guiding the dynamic progression from mutual antagonism to synergistic promotion (124). The evidence presented here supports functional crosstalk between apoptosis and autophagy, as observed in autophagy-driven apoptosis via P62/Fap-1, ATG12/Bcl-2/Mcl-1 and truncated ATG5, caspase-mediated disruption of autophagy, and Bcl-xL as a key regulatory node balancing both pathways. Apoptosis and necroptosis interact across different stages, collectively driving the progression and amplification of injury. In renal IRI, cell death exhibits a temporally distinct biphasic pattern. The first wave is directly triggered by the initial insult, including ischemia or toxins, and primarily manifests as apoptosis or acute necrosis. Subsequently, cytokines, such as TNF-related weak inducer of apoptosis (TWEAK), persistently activate death receptor pathways. This initiates a delayed but more extensive second wave. During this second wave, necroptosis acts as an upstream event. MLKL mediated membrane rupture releases DAMPs. These DAMPs exacerbate oxidative stress and inflammatory responses, thereby significantly promoting apoptosis. The two death modalities act synergistically, jointly driving a vicious cycle that leads to the continuous escalation of tissue damage (125–127) (Figure 2d). The cellular fate is precisely regulated by caspase-8. When caspase-8 actives, it initiates apoptosis by activating caspase-3. At the same time, it inhibits necroptosis by cleaving RIPK1, RIPK3 and cylindromatosis (CYLD) (128, 129). Conversely, when caspase-8 activity is inhibited, the cell shifts towards necroptosis (130). Beyond caspase-8, RIPK1 and RIPK3 also participate in the regulation of apoptosis. Within the tumor necrosis factor (TNF) receptor signaling pathway, loss of RIPK3 kinase activity promotes apoptosis through a switch in the function of adaptor proteins (131). This network of interactions is likely a core mechanism underlying the progression from acute to chronic injury accompanied by uncontrolled inflammation in renal IRI. In aggregate, these findings validate experimentally supported crosstalk between apoptosis and necroptosis, as underscored by caspase-8 serving as a molecular switch and loss of RIPK3 kinase activity that promotes apoptosis. Based on the evidence reviewed above, a tentative hierarchy within the PCD network in renal IRI can be proposed. Mitochondrial dysfunction and ROS production serve as the central initiating hub at the apex of the hierarchy. Downstream, the network branches into parallel but interconnected pathways. Necroptosis and pyroptosis appear to dominate during the early inflammatory phase. Ferroptosis becomes increasingly prominent during the reperfusion phase, when iron accumulation and lipid peroxidation peak. Apoptosis may represent a default pathway that is engaged when other routes are blocked. Cuproptosis remains the least characterized component. Its position in the hierarchy may be context-dependent rather than fixed. Autophagy occupies a unique position, functioning predominantly as a negative regulator at baseline but potentially switching to a pro-death role under extreme stress. Importantly, this proposed hierarchy is not static. The relative contribution of each pathway likely shifts over time and varies across cell types. Limitations and uncertainties in the current PCD network model Despite growing evidence supporting a coordinated PCD network in renal IRI, several important limitations and uncertainties must be acknowledged. Translational relevance from preclinical models to human disease remains uncertain and clinical validation is lacking. Most studies have been conducted in rodent models. It remains unclear how faithfully these findings translate to human renal IRI. Species differences in the expression and regulation of key cell death mediators, such as GSDMD, MLKL and GPX4, may limit direct extrapolation. To date, no therapy targeting the PCD network has been approved specifically for renal IRI. The safety of long-term modulation of these pathways in humans also remains unknown. Spatiotemporal dynamics and cell type-specificity of the network are poorly defined. Most studies examine a single time point This makes it difficult to capture the dynamic, time-dependent nature of the network. The temporal sequence of activation of different PCD pathways and the critical time windows for therapeutic intervention remain unknown. Furthermore, nearly all data come from bulk tissue analysis, which cannot distinguish cell type-specific contributions. The PCD network likely operates differently in proximal tubular epithelial cells, distal tubular cells, endothelial cells and infiltrating immune cells. In contrast to the well documented crosstalk of pyroptosis and ferroptosis, the interplay of cuproptosis with other PCD modalities remains the least characterized. To date, only the connection between cuproptosis and ferroptosis has been explored. Its interactions with pyroptosis, necroptosis and autophagy have yet to be fully elucidated. Further studies are therefore warranted to define the relative contribution of cuproptosis within the broader PCD network in renal IRI. The functional consequences of pathway redundancy and compensation are poorly understood. When one death pathway is inhibited, it is unclear whether other pathways reliably compensate.It is also unclear whether such compensation is beneficial or harmful. This knowledge gap has significant implications for the development of combination therapies. Addressing these limitations will require refined animal models that better recapitulate human disease. It will also require dynamic monitoring of pathway activation using novel biomarkers and single-cell multi-omics approaches to resolve cell type-specific network architecture. Despite these uncertainties, the framework of a PCD network provides a valuable conceptual foundation for understanding the complexity of renal IRI and for developing next-generation therapeutic strategies. Broader implications: PCD networks in other kidney diseases While this review focuses on renal IRI, the concept of an integrated PCD network is also relevant to other common kidney diseases, such as chronic kidney disease (CKD) and diabetic kidney disease (DKD). Understanding how these networks operate in different disease contexts may reveal shared pathophysiological mechanisms and disease-specific therapeutic opportunities. Emerging evidence suggests that similar PCD networks occur in CKD. GSDMD mediated pyroptosis plays a protective role by suppressing necroptosis. Moreover, the balance between these two pathways determines the outcome of CKD (132). Autophagy negatively regulates pyroptosis by clearing damaged mitochondria and limiting ROS driven inflammasome activation, thereby alleviating 3-MCPD-induced renal injury (133). Cuproptosis enhances ferroptosis by upregulating substrate for lipid peroxidation, such as PE, and by damaging the antioxidant protein GPX4 (134). Furthermore, restoration of autophagy and suppression of apoptosis act synergistically to ameliorate intestinal barrier dysfunction in CKD (135). In some contexts, different PCD pathways act cooperatively rather than antagonistically. In a rat model of CKD, both necroptosis and apoptosis contribute to the progressive loss of renal tubular cells. Notably, necroptosis predominates in driving tubular cell loss and CKD progression (136). Moreover, PANoptosis in CKD operates as a flexible “death signaling network” that integrates key molecular components from pyroptosis, apoptosis and necroptosis. This network is a major contributor to renal tubular epithelial cell injury and the progression of interstitial fibrosis. The underlying mechanisms involve inflammation, oxidative stress and fibrotic processes. Several PANoptosis-related genes, such as prostaglandin G/H synthase 2 (PTGS2) and protein c-Fos (FOS), show abnormal expression patterns. PTGS2 is upregulated, where it may drive epithelial-mesenchymal transition (EMT) and accelerate renal fibrosis via the TGF-β/SMAD family member 3 (Smad3) axis (137). In addition, overexpression of FOS positively correlates with tubular atrophy and inflammatory infiltration in CKD models. Notably, certain traditional Chinese medicine formulas have been shown to slow CKD progression by downregulating FOS expression, possibly through interrupting the activator protein 1 (AP-1)/TNF-α positive feedback loop (138). The PCD network in CKD is characterized by multifaceted crosstalk. Pyroptosis and autophagy exert either protective or detrimental effects depending on the context, whereas cuproptosis and ferroptosis amplify injury, as well as necroptosis drives tubular cell loss. Meanwhile, PANoptosis primarily promotes tubular injury and interstitial fibrosis. This complex regulatory architecture highlights the importance of context-dependent modulation of cell death pathways for therapeutic intervention in CKD. Accumulating evidence indicates that similar PCD networks operate in DKD. Their intricate interplay and mutual modulation have been increasingly recognized. Pyroptosis and ferroptosis act synergistically to promote the progression of DKD. Moreover, these two forms of cell death share common upstream regulators, namely mitochondrial damage and ROS (139). Similarly, ferroptosis and apoptosis cooperate to exacerbate podocyte injury and inflammation in DKD (140). In DKD, autophagy negatively regulates ferroptosis, as demonstrated by decreased lipid peroxidation and free iron accumulation, as well as increased levels of GPX4 and SLC7A11 (141, 142). An inverse relationship exists between autophagy and apoptosis. Thus, promoting autophagy can suppresses apoptosis, and this reciprocal regulation contributes to delaying DKD progression (143, 144). In DKD, PANoptosis is activated through the tumor necrosis factor ligand superfamily member 10 (TRAIL)/tumor necrosis factor receptor superfamily member 10B (DR5) signaling axis. Upon binding to its death receptor DR5, TRAIL triggers the assembly of a PANoptosome complex containing caspase-3, caspase-1 and MLKL. This complex simultaneously initiates apoptosis, pyroptosis and necroptosis. This integrated activation of multiple cell death pathways disrupts podocyte membrane integrity, releases pro-inflammatory mediators and promotes glomerulosclerosis. The activation level of the TRAIL/DR5 axis in podocytes positively correlates with disease severity in DKD patients (145). Although exogenous TRAIL administration improves renal function as well as glomerular and tubular morphology in diabetic mouse models, it has little effect on proteinuria (146). Collectively, the PCD network in DKD is characterized by synergistic interactions among pyroptosis, ferroptosis and apoptosis, which collectively drive disease progression. Autophagy serves as a protective counterbalance by negatively regulating both ferroptosis and apoptosis. Additionally, PANoptosis, activated via the TRAIL/DR5 axis, integrates multiple cell death pathways to exacerbate podocyte injury and glomerulosclerosis. Modulating the key regulators that maintain the balance among these interconnected cell death pathways may provide new therapeutic approaches for DKD. In summary, integrated PCD networks are a conserved pathophysiological feature across renal IRI, CKD and DKD. While core crosstalk mechanisms are shared, disease-specific triggers, cell types and temporal patterns exist. Understanding these shared and distinct features is critical for developing tailored therapies. The interconnected nature of these pathways suggests that optimal outcomes may require network-based interventions rather than single-pathway inhibition. Therapeutic strategies targeting the PCD network Traditional drug development follows the linear paradigm of “one gene, one target, one disease”. It has achieved preliminary success in the early exploration of renal IRI, leading to the generation of various inhibitors that target key nodes of specific cell death pathways. However, the challenges encountered in clinical translation have unveiled a deeper pathological reality. The cell death network is characterized by redundancy, compensation and dynamic evolution. Consequently, therapeutic strategies must adapt accordingly. They should shift from attempting to “precisely destroy a single stronghold” toward “systematically regulating the entire battlefield”. We begin by reviewing the achievements of node-specific inhibitors and their inherent “compensation dilemma”. Subsequently, we focus on elucidating the next-generation strategies designed to overcome these limitations, including multi-target and network modulation approaches. Finally, we explore the frontier directions of utilizing emerging biotherapies and agents for the systematic remodeling of the death network (Figure 3). Currently, the majority of these drugs are still at the preclinical stage (Table 1). Together, these strategies form a complete interventional spectrum ranging from microscopic inhibition to macroscopic regulation. Ultimately, they aim to achieve effective control of renal IRI as a complex systemic disease. Integrated therapeutic strategies targeting the PCD network. Node-Specific Inhibitors. These inhibitors target key molecules of single pathways, including NLRP3, GPX4 and RIPK1. They represent the strategy with the broadest current research foundation and the most concentrated body of evidence. Multi-Target and Network Modulation Approaches. This core direction for transitioning to systemic intervention primarily includes upstream defense activation, for example Nrf2 activators, multi‑target drugs or combination therapies, such as dual‑pathway inhibitors, and shared stressor modulation, for instance mitochondrial protectors. This area is a key growth field for breaking through the current efficacy bottleneck. Emerging Biotherapies and Agents. This encompasses biological agents based on exosomes, nucleic acid drugs, cell therapies, multi-effective natural products and the repurposing of existing clinical drugs. This represents the most forward-looking exploratory field. These approaches focus on systemic regulation and intelligent delivery, providing new dimensions for future therapies. Table 1Clinical development status of therapeutic strategies targeting the PCD network in renal IRI.Therapeutic strategyTarget pathwayAgent(s)Clinical statusNode-specific inhibitorsCaspase-1 inhibitorPyroptosisVX-765Phase II (other indications)Broad-spectrum caspase inhibitorPyroptosisZ-VAD-FMKPreclinical onlyNLRP3 inhibitorPyroptosisMCC950, CY-09Phase II (MCC950 halted)GSDMD inhibitorPyroptosisDisulfiramFDA-approved (alcohol use disorder)Ferroptosis inhibitorFerroptosisFerrostatin-1, Liproxstatin-1Preclinical onlyIron chelatorFerroptosisDeferoxamine (DFO)FDA-approved (iron overload)ACSL4 inhibitorFerroptosisASPreclinical onlyRIPK1 inhibitorNecroptosisNec-1f, GSK’872Preclinical onlyRIPK3 inhibitorNecroptosisAZD5423Preclinical onlyMLKL inhibitorNecroptosisNecrosulfonamide (NSA)Preclinical onlyNetwork modulationNrf2 activatorMulti-targetBardoxolone methyl (CDDO-Me)Phase III (CKD, halted)Nrf2 activatorMulti-targetSulforaphaneClinical (dietary supplement)Combination therapyFerroptosis + necroptosis inhibitionDual-target16-86 + Nec-1sPreclinical onlyDual inhibitorFerroptosis + necroptosisZharp1-163Preclinical onlyUpstream modulatorsMitochondria-targeted antioxidantApoptosisMitoQClinical trials (other)ER stress inhibitorApoptosis/ferroptosis4-PBA, TUDCAFDA-approved (4-PBA for urea cycle disorders)Repurposed clinical drugsα2-AR agonistFerroptosisDexmedetomidineFDA-approved (sedation)AnticonvulsantNecroptosisPhenytoinFDA-approved (epilepsy)Vitamin D analogPyroptosisCalcifediolFDA-approved (vitamin D deficiency)AntimalarialPyroptosisArtesunateFDA-approved (malaria)COMT inhibitorFerroptosisEntacaponeFDA-approved (Parkinson’s disease) Clinical development status of therapeutic strategies targeting the PCD network in renal IRI. Node-specific inhibitors: success and the challenge of compensation It is important to emphasize that most therapeutic strategies discussed in this section are still at the preclinical stage. Most evidence comes from rodent models of renal IRI. And none of these strategies have been approved specifically for this indication. Therefore, while the results from animal models are promising, considerable caution is warranted when extrapolating these findings to human patients. Various inhibitors have demonstrated efficacy in preclinical models of renal IRI. Inhibitors targeting key nodes of pyroptosis primarily include caspase inhibitors, NLRP3 inflammasome inhibitors and GSDMD inhibitors. VX-765 specifically inhibits caspase-1. It effectively blocks caspase-1-dependent GSDMD activation. This significantly attenuates pyroptosis and the associated inflammatory responses. Ultimately, it ameliorates renal fibrosis (147). The broad-spectrum caspase inhibitor Z-VAD-FMK mitigates tissue injury through multi-target inhibition of pyroptosis (148). MCC950 inhibits the NLRP3 signaling pathway by blocking ASC oligomerization, thereby reducing renal damage and cytokine release (149). CY-09 exerts a renoprotective effect by directly binding to NLRP3 and inhibiting its ATPase activity (150). Disulfiram targets the downstream executioner protein GSDMD. It inhibits pore formation by covalently modifying the Cys191 residue of GSDMD. Additionally, disulfiram antagonizes TLR4 and suppresses the caspase-11-GSDMD pathway, thereby inhibiting pyroptosis at multiple levels (151). Interventions targeting ferroptosis primarily focus on its core regulatory mechanisms. These interventions utilize specific inhibitors and iron chelators. Ferrostatin-1 directly inhibits ferroptosis. In mouse models, it has been shown to significantly improve renal dysfunction and tubular damage (152). Liproxstatin-1 (Lip-1) suppresses ferroptosis by modulating early growth response protein 1 (EGR1). It also reduces macrophage infiltration and inflammatory cytokine release, thereby effectively mitigating renal IRI (153). The iron chelator deferoxamine (DFO) exerts a renoprotective effect by reducing the intracellular iron burden (154). ACSL4 is a key regulator of ferroptosis and has emerged as a potential therapeutic target. Its specific inhibitor, AS, binds to the glutamine 464 site to inhibit enzyme activity, thereby alleviating lipid peroxidation and ferroptosis (155). Inhibitors targeting key nodes of necroptosis primarily focus on three core regulatory molecules, including RIPK1, RIPK3 and MLKL. These three form a comprehensive intervention system ranging from upstream kinase inhibition to downstream blockade of the executioner protein. Necrostatin-1f (Nec-1f) inhibits RIPK1 activity. It blocks the necroptotic process and significantly improves survival rates in animal models of renal IRI (156). GSK872 is a selective kinase inhibitor that blocks RIPK3-mediated MLKL phosphorylation, thereby attenuating renal fibrosis (157). AZD5423, also a RIPK3 kinase inhibitor, shows promising prospects for clinical translation (158). Necrosulfonamide (NSA) directly acts on the downstream executioner protein MLKL. It inhibits MLKL oligomerization and membrane pore formation, exerting a renoprotective effect (159). The Hsp90 inhibitor C316–1 inhibits necroptosis by disrupting the interaction between Hsp90 and cell division cycle 37 homolog (CDC37), leading to RIPK1 degradation (160). Promising multi-target and network modulation approaches Given the complexity and redundancy of the PCD network, therapies that target a single node often have limited efficacy. Consequently, intervention strategies are gradually shifting toward multi-target approaches. These aim to simultaneously modulate several key nodes. Alternatively, macro-level strategies are being designed to reshape the homeostasis of the entire network. Similar to the node-specific inhibitors discussed above, the multi-target and network modulation strategies described in this section are also predominantly at the preclinical stage. The bulk of the evidence is limited to rodent studies of renal IRI. To date, no therapy has received specific approval for this condition. Nevertheless, they represent promising next-generation strategies that may overcome the limitations of single-node inhibition. Nrf2 activators: strengthening the core defense network Nrf2 is a master regulator of the cellular antioxidant response. Under homeostatic conditions, Nrf2 binds to KEAP1 and undergoes ubiquitin-mediated degradation (161). Under oxidative stress, Nrf2 dissociates and translocates to the nucleus. There, it activates the expression of several cytoprotective genes, including HO-1, glutamate-cysteine ligase catalytic subunit (GCLC) and GPX4 (162, 163). Consequently, activating the Nrf2 pathway enhances both GSH biosynthesis and GPX4 expression. This fundamentally strengthens the core antioxidant system that defends against ferroptosis. Furthermore, Nrf2 activation can inhibit the assembly and activation of the NLRP3 inflammasome. It also attenuates inflammatory responses, thereby exerting inhibitory effects on pyroptosis (164–166). Nrf2 activators, such as Bardoxolone Methyl (CDDO-Me) and sulforaphane, have demonstrated efficacy in improving renal function in various kidney disease models. The protective effects of these activators are closely associated with upregulation of GPX4 and inhibition of lipid peroxidation (167, 168). Combination therapy: synergistic blockade of parallel death pathways Given the presence of escape or compensation mechanisms within the PCD network, targeting two or more key and interconnected death pathways simultaneously may produce synergistic effects. This approach could yield superior therapeutic outcomes compared to any single-agent therapy. Considering that ferroptosis and necroptosis are often co-activated in renal IRI and exhibit crosstalk, combined inhibition shows promising potential. In a mouse model of renal IRI, concurrent use of the ferroptosis inhibitor 16–86 and the necroptosis inhibitor Necrostatin-1s (Nec-1s) resulted in significantly greater reduction of tubular necrosis. It also led to greater improvement in renal function and more effective lowering of inflammatory cytokine levels compared to either agent alone (95). To achieve combined inhibition more precisely and efficiently, researchers are developing single molecules capable of simultaneously targeting key nodes across multiple death pathways. The compound Zharp1–163 is a dual inhibitor that effectively blocks both ferroptosis and necroptosis. In a mouse model of lipopolysaccharide-induced sepsis-associated AKI, treatment with Zharp1–163 significantly reduced biomarkers of ferroptosis, including 4-hydroxynonenal (4-HNE) and prostaglandin-endoperoxide synthase 2 (PTGS2). It also reduced biomarkers of necroptosis, such as phosphorylated MLKL (p-MLKL). Its renoprotective effect surpassed that of single-target inhibitors, providing proof of concept for the future development of such network-targeting drugs (169). Upstream modulators: targeting shared stress sources Multiple PCD pathways share common upstream triggers, including mitochondrial dysfunction, ER stress and ROS burst. Therefore, targeting these shared stress sources can simultaneously attenuate the activation signals for multiple downstream death pathways at the upstream level. Mitochondria are the primary site of ROS production. They also serve as critical regulatory nodes for ferroptosis, apoptosis and pyroptosis. Mitochondria-targeted antioxidants, like MitoQ, which is a coenzyme Q10 derivative covalently linked to a mitochondrial-targeting sequence, can accumulate within mitochondria and scavenge ROS. Studies have shown that MitoQ pretreatment significantly alleviates apoptosis and oxidative damage in renal IRI. It preserves mitochondrial function, reduces cytochrome c release and inhibits caspase-3 activation (170, 171). ER stress drives the activation of the UPR pathway and the upregulation of CHOP expression. CHOP can concurrently induce both apoptosis and ferroptosis. Chemical chaperones, like 4-phenylbutyric acid (4-PBA) and tauroursodeoxycholic acid (TUDCA), can alleviate ER stress and restore protein folding homeostasis. In renal IRI models, treatment with 4-PBA or TUDCA has been shown to suppress CHOP expression, attenuate apoptosis and reduce dysfunction in renal tubular epithelial cells (172, 173). This suggests that mitigating the upstream event of ER stress may indirectly inhibit several downstream cell death pathways. By integrating the multi-faceted strategies outlined above, from activating endogenous defense networks, to combinatory blockade of parallel effector pathways, to stabilizing the function of key organelles, we have the potential to develop more effective and robust therapies to counteract the complex PCD network in renal IRI. Emerging biotherapies and agents: systematically modulating the death network Beyond existing therapeutic strategies, a range of natural products, clinical drugs and emerging biotherapies have demonstrated the potential to modulate the cell death network in renal IRI. They target upstream regulatory nodes or exert multi-target effects. Among these, several agents are already approved for non-AKI indications. Examples include dexmedetomidine for sedation, phenytoin for epilepsy and calcifediol for vitamin D deficiency. Other agents such as artesunate, honokiol and brazilin remain at the preclinical stage. Their repurposing potential for renal IRI requires further validation. These diverse interventions, acting on various nodes of the cell death network, provide novel perspectives for kidney protection. Regarding the pyroptosis pathway, artesunate can inhibit the NLRP3 inflammasome and reduce the expression of pyroptosis-related proteins, including caspase-1 and GSDMD (174). Similarly, calcifediol (25-hydroxyvitamin D3) exerts protective effects by reducing ROS production, inhibiting NF-κB activation and suppressing GSDMD-mediated pyroptosis (175). Furthermore, emerging cell therapies, such as fibroblastic reticular cell-derived exosomes (FRC-Exos), can promote PTEN-induced putative kinase 1 (PINK1)-Parkin-mediated mitophagy. This inhibits NLRP3 inflammasome activation and subsequently suppresses pyroptosis (176). In targeting ferroptosis, the clinically used drug dexmedetomidine is an α2-adrenergic receptor (α2-AR) agonist. It alleviates ferroptosis and associated inflammatory responses by inhibiting ACSL4 (177). Among emerging therapies based on extracellular vesicles, exosomes derived from human urine-derived stem cells (USC-Exo) carry the long non-coding RNA (lncRNA) TUG1. TUG1 regulates ACSL4 expression by interacting with serine/arginine-rich splicing factor 1 (SRSF1), thereby inhibiting ferroptosis (178). Meanwhile, the natural product cyanidin-3-glucoside (C3G) effectively mitigates Erastin-induced ferroptosis through antioxidant mechanisms. Its protective effect is comparable to that of the ferroptosis inhibitor liproxstatin-1 (179). The clinical drug entacapone upregulates SLC7A11 expression by activating the P62-KEAP1-NRF2 pathway, enhancing cellular antioxidant capacity and inhibiting ferroptosis (180). Additionally, some agents also modulate necroptosis. The anticonvulsant drug phenytoin sodium exerts a protective effect by attenuating the kinase activity of RIPK1 and inhibiting necroptosis (181). These diverse therapeutic approaches exert synergistic inhibitory effects on multiple cell death pathways, including pyroptosis, ferroptosis and necroptosis. They achieve this by modulating upstream hubs, such as oxidative stress and key signaling pathways, or by utilizing agents and biological carriers with multi-target properties. This provides a broader repertoire of pharmacological options and combinatorial treatment strategies for the prevention and management of renal IRI. Challenges and future perspectives: towards network pharmacology An in-depth understanding of the PCD network has provided a new paradigm for the treatment of renal IRI. However, translating this systemic knowledge into clinically effective interventions still requires bridging the vast gap between basic research and clinical application (Figure 4). This translation process faces three core challenges. These include targeting ambiguity due to disease heterogeneity, the lack of dynamic biomarkers to guide precision therapy and the inability of current delivery technologies to meet the need for cell-level precision intervention. These interconnected challenges collectively constitute the main bottleneck in current therapeutic development. Overcoming these bottlenecks demands that we move beyond traditional thinking. It also demands that we develop a new generation of research methods and technologies. This includes utilizing cutting-edge spatial omics technologies to map “death landscapes” at the cellular level, developing specific biomarkers that dynamically reflect the activity of death pathways in vivo and designing intelligent delivery systems for spatiotemporally precise drug release. Ultimately, these efforts will converge toward a common goal, namely constructing precision treatment strategies based on individualized “cell death network atlases” for patients. This heralds the true era of network pharmacology. A translational roadmap for targeting the PCD network in renal IRI. (a) Multidimensional research models. The foundation relies on a triad of experimental systems. These include in vitro cell models to dissect molecular mechanisms, clinical patient samples to validate human relevance and discover biomarkers. They also include in vivo animal models to evaluate holistic efficacy and systemic safety. (b) Dual core considerations for therapeutic drugs. Successful translation hinges on balancing target specificity with drug safety. Target specificity means precise action on key nodal proteins of the PCD network, such as GPX4 for ferroptosis and GSDMD for pyroptosis. Drug safety involves minimizing off-target effects and long-term toxicity. Both are paramount for clinical viability. (c) Three fundamental translational challenges. Spatiotemporal complexity arises from heterogeneity in cell death pathways due to differences in cell types, kidney regions and injury phases. This leads to targeting ambiguity. And there is a biomarker gap. The lack of specific biomarkers that can distinguish the dominant death pathways in real time and non-invasively prevents treatment personalization. There is also a delivery and specificity hurdle. Systemic drug administration causes significant off-target side effects, while kidney-specific and cell-specific targeted delivery systems remain underdeveloped. (d) Five frontier research directions and core technologies. High-resolution mapping relies on spatial and single-cell technologies to decipher heterogeneity by charting “death maps” at cellular resolution. Dynamic network modeling uses computational biology to predict key “master switch” nodes within the network. Biomarker-driven clinical trials employ liquid biopsy to enable patient stratification and therapy efficacy monitoring. Intelligent nanomedicine uses stimuli-responsive delivery to achieve spatiotemporally precise drug release at the lesion site. Genetic circuit intervention applies CRISPR regulation to offer the potential for cell-specific “fine-tuning” therapies. Challenges Despite significant advances in understanding PCD networks in renal IRI, several critical challenges must be overcome before these findings can be translated into clinical practice. These challenges span from technical limitations in current experimental approaches to fundamental gaps in our knowledge of network dynamics. They also include the practical hurdles of drug delivery and biomarker development. Spatiotemporal Complexity. The predominance of specific cell death pathways exhibits high heterogeneity across spatial and temporal dimensions. This dominance varies by cell type. Renal tubular epithelial cells are more susceptible to ferroptosis, whereas pyroptosis may predominate in macrophages (182). It also differs by renal region. The high metabolic demand and hypoxic environment of the medulla may render it more sensitive to certain death modalities (183). Furthermore, it changes with the phase of injury. The ischemic phase may be characterized primarily by apoptosis and energy metabolism collapse, while the reperfusion phase may trigger intense inflammatory and oxidative death (184). Current bulk tissue analysis techniques obscure this critical heterogeneity. This makes it difficult to identify the key cell populations driving injury and the precise molecular events involved. Biomarker Gap. We lack sensitive and specific biomarkers to map the active cell death pathways in patients in real time. Conventional renal function markers, like Scr and BUN, merely indicate functional impairment. They cannot distinguish whether the injury is predominantly driven by pyroptosis, ferroptosis, necroptosis or other pathways. For instance, there are currently no validated biomarkers to specifically detect pyroptosis, ferroptosis or necroptosis in patients with renal IRI. Examples of such biomarkers would include plasma GSDMD-N for pyroptosis, specific oxidized phospholipids for ferroptosis and p-MLKL for necroptosis. This confines treatment decisions to a “one-size-fits-all” paradigm. It prevents personalized medication based on an individual patien’s real-time “cell death pathway profile”. Consequently, the success rate of targeted therapies is significantly limited (185). Delivery and Specificity. Even if effective targets and drugs are identified, achieving kidney-specific or even cell type-specific drug delivery remains an unsolved challenge. Systemic administration often leads to unacceptable side effects due to off-target effects. Furthermore, the kidney’s complex structure and hemodynamic characteristics make targeted drug enrichment difficult. Developing safe and efficient targeted delivery systems is therefore an essential pathway to avoid systemic toxicity and improve the therapeutic index (186). Future directions High-Resolution Mapping. Future research should systematically apply spatial transcriptomics, single-cell multi-omics and multiplexed immunofluorescence imaging to renal IRI tissues from both humans and animal models. The goal is to construct a cell-resolution activity map of the PCD network across both temporal and spatial dimensions. This will allow precise identification of “hotspot regions” where specific death pathways are active and key vulnerable cell subpopulations. Thus, it will provide a “battle map” for precise intervention (187). Dynamic Network Modeling. Based on high-throughput mapping data, dynamic computational models of the PCD network in renal IRI should be constructed. These models will simulate the interactions and compensatory relationships between different death pathways. Through network perturbation analysis, they can predict key control nodes, also called “master switches”, that exert a global influence on the entire network. These nodes may not be the terminal executioner proteins of a single death pathway. Insteda, they may be common upstream signals, such as specific redox sensors or metabolites, that regulate multiple pathways. Targeting such nodes might reshape the entire network more efficiently than inhibiting a single pathway (188). Biomarker-Driven Clinical Trials. Future efforts must focus on developing non-invasive and dynamic detection methods capable of reflecting the dominant PCD pathways in vivo. For example, cleaved GSDMD-N serves as a pyroptosis marker. Its plasma levels could identify patients with active inflammasome signaling. Specific oxidized phospholipid species, such as PE-AA-OH, which is a downstream product of ferroptosis, could serve as a pharmacodynamic readout of lipid peroxidation. In addition, p-MLKL acts as a necroptosis executioner and could be a candidate plasma marker. Beyond blood-based markers, liquid biopsy approaches using urinary exosomes represent a particularly attractive non-invasive tool for renal IRI (189). Urinary exosomes can carry cargo derived from injured renal tubular epithelial cells, including GSDMD-N, p-MLKL, GPX4 and lipid peroxidation products. Monitoring these exosomal cargoes in serial urine samples could enable real-time, kidney-specific assessment of the dominant death pathway activity, without the need for invasive renal biopsy. By utilizing such biomarkers, patients with AKI could be precisely stratified in clinical trials. This work paves the way for targeted therapeutic trials. This approach would significantly enhance the success rate of clinical trials and the response rate to investigational drugs (190). Intelligent Nanomedicine. Design stimulus-responsive nanoparticles as drug carriers. These particles can achieve preferential accumulation in the injured kidney through the size effect or via surface-modified targeting ligands. More importantly, they can sense the local pathological microenvironment, including low pH, high ROS or specific enzyme activity. They can use these cues as triggers to release drug combinations in a sequential or synergistic manner, in a controlled fashion, at the right time and location. This enables “on-demand therapy”, maximizing efficacy while minimizing side effects (191). Genetic Circuit Intervention. Explore the use of CRISPR-based gene regulation technologies, which offer unprecedented potential for spatiotemporal precision in intervention. By designing specific guide RNAs and regulatory modules, the expression of key network nodes, such as GPX4 and GSDME, can be dynamically fine-tuned in a time- and cell-specific manner during the injury process. This “fine-tuning” of critical network nodes, rather than a simple “on/off” switch, may better align with the logic of physiological repair. It paves the way for truly “cell-precision medicine” (192). Potential Risks and Ethical Considerations. While the future directions outlined above hold great promise, they also present potential risks that warrant consideration. High-resolution single-cell and spatial omics technologies generate vast amounts of data. This raises important questions about data management, interpretation and patient privacy when applied to human samples. The development of intelligent nanomedicines and genetic circuit interventions, while innovative, may introduce unforeseen off-target effects or long-term safety concerns. For instance, CRISPR-based gene regulation could potentially lead to permanent genomic alterations if not carefully controlled. Moreover, the translation of network-based combination therapies into clinical practice will require rigorous safety evaluations. This is needed to avoid unintended synergies that might exacerbate tissue injury rather than mitigate it. Therefore, future research should not only focus on technological innovation but also prioritize the development of robust safety assessment frameworks and ethical guidelines for these emerging interventions. Conclusion The pathogenesis of renal IRI is best understood as the coordinated output of a dynamic, interconnected PCD network. It is not a struggle among isolated death pathways. Pyroptosis, ferroptosis, cuproptosis and necroptosis are interconnected through shared triggers, molecular switches and positive feedback loops. Together, they form a system that amplifies injury. While targeting individual network nodes has shown promise, therapeutic breakthroughs will likely require strategies grounded in a network-level understanding. They include rational combination therapies, multi-target agents and ultimately interventions that are precise in both space and time, guided by high-resolution patient data. Embracing this network paradigm is crucial for translating our complex mechanistic understanding into effective treatments for renal IRI and beyond.